Q2 2020 ICON PLC Earnings Call
[music].
Ladies and gentlemen, thank you all free standing by and welcome to be skew to try to Tracy I can you don't see earning conference call.
Probably not publish a bunch will be on they listen only mode. There will be a presentation followed by question answer session that would sign should you wish you asked the question you read the press star and another one of the telephone and wait for any could be an ounce I'm just like all of this conference is being recorded today Thursday to 23rd of July 2020.
Ended up any party than they have with like the hand, the call in French over their price speaker for today Mr. Jonathan curtain. Sir. Please go ahead.
Thanks, you know good day, ladies and gentlemen, thank you for joining us on this call covering the quarter ended June Thirtyth Twentytwenty.
Also on the call today, Weve or CEO, Dr., Steve copper and our CFO Mr. Brendan Brennan.
I'd like to note that this close webcast and out there our slides available to download on our website to accompany today's call.
Certain statements in today's call will be forward looking statements. These statements are based on management's current expectations on information currently available, including current economic and industry conditions.
Actual results may differ materially from those stated or implied by forward looking statements due to risks and uncertainties associated with the company's business and listeners are cautioned that forward looking statements are not guarantees of future performance.
Forward looking statements are only as of the data that they are made we do not undertake any obligation to update publicly any forward looking statements either is or either as a result of new information future events or otherwise.
More information about the risks and uncertainties related relating to these forward looking statements may be found in the FCC reports filed by the company.
This presentation includes selected non-GAAP financial measures for presentation of the most directly comparable GAAP financial measures. Please refer to the press release statement head of 'cause condensed consolidated statements of operations U.S. GAAP.
On audited.
Non-GAAP financial measures are not superior to or substitute for the comparable GAAP measures. We believe certain non-GAAP information is more useful to investors for historical comparison purposes.
We will be limiting to call today to one our would therefore off participants to keep your questions to one each with an opportunity to ask one related follow up question.
I would now I'd like to hand, the call over to our CFO Mr. Brendan Brennan.
Thank you gentlemen.
In quarter, two we achieved to gross business wins of $1 billion, an 18 million and recorded 117 million worth constellation. Consequently, net awards in the corner were $910 million, resulting in a net book to Bill of 1.47 times.
With the addition of these new awards on backlog grew to $9.1 billion. This represents a year on year increase of 11%.
Revenue in quarter, two with $620.2 million. This represented a year on year decreased 10.8% or 10.3% on a constant currency basis.
Our top customer represented 12.1 presented revenue for the quarter compared to 12.9% in quarter two 2019.
Hi, customers represented 40.9% quarterly revenue compared to 26.9% of last years.
10 represented 54.9% compared to 49.5 last year, what our top 25 represented 71.2% compared to 69.5% last year.
Gross margin for the quarter was 28.1 weekend compared to 29.3% in quarter, one and 29.4% in the composite quarter last year.
All right today was 13.5 percentage of revenue in quarter, two which compared to 12.2 last quarter and 12% in a couple of period last year.
Operating income for quarter, two with $75 million a margin of 12.1% this compared to 14.9% last quarter on 15.3%.
Powerful quarter last year.
The net interest expense was $2.8 million for the quarter and the effective tax rate was 12%.
Net income attributable to the group for the quarter was $63.6 million a margin of 10.3% equating to diluted earnings per share of $1.20 cents.
This compares to earnings per share of the dollar 70 in quarter $1.69 and comparable quarter last year.
Net accounts receivable were $490.2 million trophies in June 2020. This compares with net accounts receivable balance of $585.9 million.
First of milestones for any.
This reduction was entirely driven by positive movements in days sales outstanding on the deposit basis. They said it's done were 53 days at June 30 Twentytwenty.
This compares with 55 days in the March Twentytwenty and 61 days at the end of June 2019.
Cash generation from operating activities in the quarter was $117.9 million.
It's your chart 20 trading company had a growth cash balance of $594 million and debt of $350 million, leaving a net cash bonds $244 million.
This compared to a net cash all under $24.4 million at March 31, Twentytwenty and net cash of $81.8 million at June versus 2019.
Capital expenditures during third quarter was $9.9 million as no shares were repurchased during the quarter.
In addition to the significant in cash profile and currently have undrawn revolving credit facility, a $150 million available to use.
Our robust cash generation and strong access to liquidity plus isn't it very resilient position as we work through the challenges that 20 to 20 brands.
During the quarter, we took a restructuring charge of $18 million as we continue to improve the efficiency of our operating model. This restructuring plan reflected rationalization across the business, where we moved resorts usually utilization and our office footprint. As result of this our GAAP earnings per share were 90 cents.
Compared to $1.20, our non-GAAP basis would all that said like how the call to seize.
Thanks, Brendan and good morning to you all.
During the quarter, we continue to see strong RFP flow and robust levels of demand in the market as customers across all market segments continued to outsource more of the development work to icon.
Particular, the biotech funding environment remains buoyant and the strong focus on covered non team work across our sponsor base is providing autohome with a solid foundation of faster than will foster burn projects as we transition through this and limit.
As a result, we booked a strong levels of gross and net awards of 1.0 billion and $910 million, representing a book to bills of 1.74 and 1.47, respectively.
In doing so we grew our backlog year over year by 11% to $9.1 billion.
As we predicted on our quarter one pool quality results were significantly influenced by the impact of the current of ours pandemic on smartphones clinical operations.
During the quarter, we delivered revenue of 620.2 million at a solid gross margin of 28.1% what are well executed cost optimization plan enabled SGN I expenses to be reduced from quarter, one and held steady over the year, allowing us to deliver earnings per share of.
$1.20 cents.
Over the course of the quarter, we've been dealing with a challenging clinical environment, which continued to evolve rapidly.
Our phase two to four business remained the service was most impacted.
With the second half of from the second our March we saw new trials starting to be put on hold patient enrollment slowing at our sites restricting or stopping access for SCR rise.
As the buyers continue to spread the effect worsened with well over 70% of all SaaS impacted at its peak in the late April an early may.
Since that time, we've seen a recovery of between two and 4% per week in the number of saw its reopening with approximately 60% of saw its probably impacted to some degree.
We remain alert to the threat to the second wave in the fall own due to a continuation and escalation of the first wide as appears to be the case in the United States, where we have seen the pace of side reopening slow from 4% per week to 2% currently.
Nevertheless, although a full recovery is likely to be delayed until early next year. It is not reversed the positive trends so far and consequently, the number of saw its declining or delaying. These studies decoded 19 is significantly reduced compared to what we saw during the peak.
Intelligently size initiation have been particularly strong in recent weeks, mainly due to the large amount of coated related work. We have one in recent months and the backlog of sites, which were closed during the peak the lump them.
In addition to those ongoing sought dynamics patient recruitment also remains a leading indicator for the pace at which clinical trials or recover.
At the peak of the pandemic in April we saw an 80% to 90% reduction in patient enrollment compared to pre totaled 19 levels.
This was due to the combination of global site closures as well as patients avoiding hospitals and complying with travel restrictions and lockdown.
Since then however, we've seen a steady improvement in patient accrual to the point, where enrollment levels and now closer to 40% of pre coated levels.
And with some large trial, starting we expect this upward trend to continue.
This improvement has been helped by our ability to leverage our at home patient services delivered through our Symphony clinical research group, which has seen an unprecedented surge in demand over the past four months.
In addition through a seller care, our global seismic work, we're able to provide a proven method to engage physicians and patients in clinical research programs.
Our embedded staff of direct access to the such database, which helps evaluate the patient population during the study feasibility phase increasing enrollment and making clinical trial participation a much more efficient and enjoyable process for the position.
In the main Todd we continue to proactively review and implement alternative trial monitoring approaches with customers on a study by study basis, including remote and risk based monitoring.
This pandemic has driven an accelerated need for remote monitoring we've adapted quickly.
Decreasing remote monitoring from only 5% of our visits in quarter, one to almost 60% in quarter two.
However, significant impediments to remote monitoring as a total replacement of on sought monitoring can exist in some regions, particularly Europe.
And in these cases, we've seen a steady returns on site monitoring as such we open.
Nevertheless, there is little doubt the pandemic will continue to be a significant catalyst for change in this space and it is unlikely we will ever return to the precursor days of exclusively on side monitoring business for some projects.
With respect to our other service lines in our central laboratories sample volumes received into our facilities have improved.
With the current reduction in activity at around 25% of normal levels relative to the 40% drop we saw in quarter one.
We continue to grow this expected as the coded work ramps up.
Further our docs functional solutions business continues to perform very well, we are expecting strong year over year revenue growth in that gene.
As we are bond on our quarter one call. We made the typical decision to implement immediately and proactive cost reduction measures to protect jobs maintain our business performance and show that we were ready to move quickly when business conditions improve later in the.
These ongoing initiatives, including hiring freezes in certain business units the removal of some contract staff the reduction of Nonlabor variable spend in discretionary areas and a temporary salary reduction for employees.
These decisions will not taken lightly at the time and have since been under continuous review as part of our operational and financial forecasting process.
In response to both the gradual improvement of global clinical trial activity and better visibility of the impact of covert 19 on icons business for the remainder Twentytwenty. We're pleased to announce at the measures related to staff salaries will be concluded at the end of August.
I'd like to thank all of our employees for their resilience flexibility and understanding over the last three to four months.
Our industry, leading balance sheet goes from strength to strengths, we continue to make excellent progress and this quarter. We further reduced our dsos to 53 days down from 61 days and the corresponding quarter last year.
Consequently at the end of quarter, two we had a net positive cash balance of $244 million, which leaves us well placed to face any short term pandemic challenges, while positioning ourselves will for future M&A optune opportunities that may present.
As we look forward, although the impact of the pandemic continues to evolve I want to take this opportunity to reinstate our full year guidance.
We expect 2020 revenues to be in the range of 2.65 billion to $2.75 billion as earnings per share to be in the range of $6 to $6.50.
Before moving to QM I'd like to thank the entire icon team.
Our focus remains protecting the safety and well being of our employees and patients as we continued to deliver the important work we undertake on behalf of our customers.
We feel we are fulfilling our vision and mission through the role we play in a search for vaccines and other treatments against covered 19 run incredibly proud of our entire workforce and I'd like to thank them for their tireless efforts and ongoing resilience during this unprecedented period.
Thank you everyone and we're now ready for questions.
Thank you, ladies and gentlemen will now begin the question answer session.
As a reminder, should you wish to ask a question youre going to compress bar on the number one of the telephone and make principal amounts to do we should concentrate in your press the pound or hash key once again, it's far anyone for question.
Our first question comes from the line so I got from Evercore. Sir. Please go ahead language now.
Thanks, Good morning, good afternoon guys.
So I guess is more of an industry question you know with all the vaccine trials Alcobra work that we've been talking about.
And patient recruitment has always been a major bottleneck within the industry and all of that could work that's going to you guys think if there's enough patients out there for US again, a vaccine in an ex like by early 21.
Yeah lucrative it's a good question I'd split a split the trials into two parts treatment trials, one and prophylactic vaccine trials or the other I think in the treatment trials, there is going to be a lot of competition.
When they will tend to be within hospitals, and they'll be trials that will be competing for patients who actually have the the infection and a needed to be traded on the other on the other side of it on more the vaccine side of things were looking for relatively healthy people, who obviously, a potentially going to be exposed to the virus.
Looking to track does as a large scale. Many many thousands of patients and we're monitoring and well be monitoring and I think those trials will be easier to request I won't be easy, but there will be easier to recruit whereas the treatment trials I think we'll have a significant amount of competition toward split it into two areas.
The large large scale ones, probably easier the treatment once a bit more difficult because there is a lot of focus on on obviously on this area in terms of regulatory regulatory start up and moving things along so.
I do think these trials will burn faster than our normal sort of studies.
Okay, and I guess more specifics you guys, where youre thinking about how gross will trend throughout the rest here it looks like a fire guar guidance, it's almost getting back to US flat by then the fourth quarter and then you look at the work that's being pushed out all the covert work that you're doing now.
Plus all the RFP and the contract work that you're signing to date that might start up and 21 is there is there enough capacity for you guys to really make up all of the lost ground from 2020.
Yeah, we we certainly see our work ramping up in the second part of the as you mentioned the fed recovered work and as the sites come back online Bcf studies coming back to normal we're already seeing.
Significant uptick in our site initiation sub some of that is total, but it's not all targeted site initiations and getting studies moving again, a study randomizations as I mentioned is still down enrollment is still down, but we still we still see that coming back to a more normal level, probably realistically early in the year will be.
Q O Q1 next year and we believe we can ramp up our resources appropriately we haven't had any major reductions in both so we have people.
Ready to move and we are we do believe we're going to be able to move that on and do the appropriate recruiting that will need to do in order to drive as it to complete that working to do that as a sort of numbers.
Great. Thanks.
Thank you for next consumer comes from the line of Bob Jones from Goldman Sachs. Please go ahead, Bob Lyons Council.
Great. Thank you I guess, just a follow up on the the Kobin questions. Obviously, a lot of focus there yeah. I would you guys are willing to share what portion of the 910 million of bookings came from Kobin related work and then.
As we think about what's in the pipeline you guys. Obviously mentioned a very robust pipeline as we think about three Q.
Any context, you could add as far as just how much incremental covert work.
You are seeing that could potentially show up in awards for Threeq you.
Yeah, but we are told that sort of specific percentages, but its you know it's reasonably substantial certainly above the 20% Mark in terms of the the the work for the current quarter in coated.
And so the pipeline is strong the work has been coming in we feel where it vaccine work is one of our core competencies we.
We feel we want to we've won the awards for the best a hero in the vaccine space number of times, we have very good people in that area and.
So we feel we have with competitively advantaged in the vaccine space and that's I think seems to be playing through in some of these awards I think going forward, we're still seeing a number of opportunities both in the treatment and the vaccine is prophylactic area coming through so so we expect that sort of level to continue in that in the short to medium.
Obviously as.
The vaccines in the trials come to fruition and.
Decisions Allied they'll probably be less work, but I don't think it's going to go away completely I do expect to see work in this area continue for probably several years as as the vaccines continue and they look to improve the various vaccines that I have no doubt will come through over the next 12 months also.
Now that's helpful and I guess, maybe Brendan just one on the margins and I noticed you.
Mentioned, excluding $18 million from restructuring charges. So curious about what that maybe gross dollar cost savings was related to that and then more importantly.
How much cost savings is there a assumed in the guidance it does seem like the margins.
Our implied to improve slightly up throughout the back half relative to the first half.
Yeah, Bob there's probably for the for the for the remainder this or the way we're looking over the course of this year, if I look at something in the ballpark. The mid single digits in terms of millions of dollars for cost savings from those those initiatives.
As we sit in going through and I think your second part of your question was around that the margin profile the pickup at the back half as I correct.
That's right yeah. It seems like it's implied to improve a better just curious how much of that was just.
Leverage versus potential cost savings from from these programs I.
I think it does does does starting programs, where as you know just more more as we look at the flexibility and optimizing and utilization of our headcount on our office footprint.
So you know as we as we look to the back ended the year and you've seen in the guidance that we issued now and they're obviously using flight revenue ramp and that's really thought well and push the margin in the right direction as we maintain our good cost control in Q3 in Q4 separately, but I think the biggest predominant piece will be.
Seeing the continuing progress that we have done that size at levels in terms of reopening and in terms of that randomization of patients at continuing in Q3 in Q4 African say that I think the revenue should be there to be able to drive the margin profile together.
Okay makes less sense. Thank you.
Thank you next question comes from the alignments.
John costs Maam. Please go ahead your line is now.
Hi, good afternoon. Thank you very much for the questions.
If you guys take a look at your.
I hear awards outside of the covert work have you sensed any differences in approach amongst large pharma progress midsize customers and small biotech and in particular, we had heard inklings of large pharma delaying decision making.
On starting new programs, but wondering if youve seen any of that in practice.
You know the short answer I think is no on that we certainly seeing a strong biotech environment a reference that in my comments the funding environment remains buoyant.
That's a continuing moves and over the last few years and that reflects that's reflected in our in our wins, but we still maintain a large component in our backlog of of large pharma or not.
Hesitate to say, we've seen any sort of significant delays in those awards this point John.
Okay. That's good to hear and then can you just talk I guess higher level here can you can you talk about the mindset.
You are large pharma customers in terms of whether the pandemic is causing them to rethink the outsourcing paradigm in other words are the conversations that you're having with customers, who would typically lean more towards preferring in house or epic pain different today than they were before the pandemic or are you seeing FSP customers use more of your functional served.
Okay.
And recognizing that we're nowhere near the point of being done with a pandemic, but coming out of that do you think this period kind of moves the needle in terms of outsourcing penetration.
I think it's probably a little early to answer that question.
We've certainly seen a strong performance from our functional services group, it's been a significantly less impacted I mentioned.
Ravi growth strong year over year growth in that area.
We were able to secure a couple of very significant partnerships in that area and those have continued to play out. So it's been less impacted I guess, that's a decision customers of bye.
It's a business, obviously based more on fts and resources than it is on activities and hence.
The reasons best not a tough to knows but likely related to continuation of those resources. They've they've continued that work. So that's been a positive for us in our business and I said I think that'll that'll continue as we work through the pandemic I think it's too early to sort of asked the question as to whether our largest.
Our customers, particularly a rethinking outsourcing approaches.
Think it's probably too early to think that pushing towards NFS piece a type of situation.
Really.
I can answer that question, probably probably and take another year I think before that.
That question can really be aren't where in the middle of this at the moment and everybody is trying to get done what what we had planned and what we started and try to reaccelerate. The study so it's a bit earlier to answer that.
Okay. That's fair enough. Thank you.
Yes.
Thank you. The next question comes from the line as David Windley from Jefferies. Sir. Please go ahead flying solvent.
Can you talk economy they would.
Hello, David are you on mute.
Dave Windley translate agreements.
[laughter].
Okay now, let's take me quite Simops that may happen.
I'm not fun.
Please go ahead Jack lines now.
Thank you.
I appreciate the Irish pronunciation of men.
So.
Hi, Steve I was hoping you could just provide a little bit more color on the economic says you know well first some just a little bit more color on some of the work you might be doing related to covert vaccines and what the economics might look like.
Some of these trials go from phase two to phase three.
We've heard some this work might be discounted, but I was also curious why that might be the case. If you know we're trying to solve a global pandemic don't you want to put all the resources toward best that you would want to.
Sure Jack.
No I don't think owed call out any specific with different surround the economics of the work if anything.
Our customers have been pretty clear to us that they need these studies resourced.
And and backup resource so so we've been asked to.
I have contingency plans in place that they're happy to to painful.
So absurdly low.
I would certainly contest any assertion that things are being discounted if anything were being after the site or have a contingency resulted in place and have backup plan. So that if anything happens.
In terms of out stop all the sites out that we are ruybal dataset been a mitral. These trials run on time and on a daily gets delivered our customers have a very very serious about.
About solving this crisis and about getting these vaccines the market.
I've been around this industry Napa 2030 years, although I think I've ever seen the sort of urgency that I've seen over the last three or four months in terms of getting these sites up and that includes regulators.
Sponsors all of US aside staff everyone's very much pulling a no real thought about discounts or early that it's let's do whatever types to get it done is the attitude.
Great and I was also hoping you could provide a little bit of color around the central lab business just relative to the total company performance in the quarter.
How did that do and does the shape of the recovery look a little bit different here any color there would be great.
Oh, the central level Brendan can jump in on this or the central lab is relatively small part of our business well under 10%, but it's an important part of our business had a business it's been growing nicely over the last a few years. We we bought on we acquired as you probably remember molecular India and I've been a very very successful act.
Position given us some extra horsepower in terms of all the oncology solving sister pathologies that are such that that's that's been an excellent acquisition in one it's really contributed very well to the growth of our central lab, we've been able to I think we've alluded to in the past bring on some new significant customers and some relatively large partnerships in the low.
Lab side of things.
The coated opportunity or put it that way as also afforded us.
Opportunities for growth that's not the size. It we are those as I've said, we were down 40% example, accessions.
Early in the year Thats now back to more like 20% to 25%. We do think the second half of the year is going to be significantly stronger for our lab group and in essence, they'll come back maybe maybe not to you on your growth profile. We certainly believe theyre going to can be a blodgett large part of the of the growth story in the second half of the.
And beyond that so.
I'm really pleased with the why the lab as a as performed and it continues to perform particularly with as say the various aquas the acquisitions, we've done there and the new partnerships at Bruno.
Brendan did you want to add anything on that one.
I think I think is over both Dave.
And maybe just to say Jackie will I mean, if you're looking you know that business as a as Steve said it is that attempts at the overall business, but its trend in terms of Q2 wasn't significantly out of line with the rest of the organization. So we called out that the group was down about 10% they werent quite significantly as line with that but we again like the rest of the business, we do see them.
Ramping back up significantly in Q3 and four.
Great. Thank you guys.
Hey, good. The next question comes from the line up one on one banner from Bank of America. Please go ahead blinds now open so.
Thank you are good morning, I apologize. If this was asked before I have to be on another call right. On my first question is on GAAP gross margin.
Your performance there was better than expected. So can you remind us what water summer a cost containment measures are you implement petting how prepared do you think you are from a capacity and employee morale perspective for when things are rebound and the fourth quarter or early next year.
Yeah. Thanks, one on the MSR off and this one anyway in terms of gross margin. Obviously, we did have a 28.1%.
Gross margin in the quarter.
As as we talked about on the last call backing in Q1, where we're talking in April we obviously brought a range of different cost containment measures to to the organization at that point.
Including you know obviously you know that there's no travel there is no you know we were looking very closely at our recruitment or we were really looking out at contractor call Center discretional cost items as well as as as some amendment to salaries and we spoke about in the last call and so I think that proportionality there.
And in all of those measures how sue to some degree during the quarter to quarter I think as we look to Q3 in Q4, I think I made the point earlier on it is much more around now kind of normalizing, where we are as an organization from a cost perspective, but still maintaining at fairly solid enough cost control of course arm.
Our already are huge focus is on ensuring lump in the business and knocking the pop Levin, our topline revenue lines over the next two quarters. So we feel we're in a good place to be able to achieve does and until then it maintained a an increase that that margin profile as we go back to something that looks more like a cadence of normal margin profile.
At that you would expect Lewis for gross margin perspective, so something closer closer to 30% as we get towards the back ended the year as Steve if he wants to comment on on either yeah, Doug jumping on the employee morale question, one we actually see their retention tick up a little bit in the in the second quoted as obviously, there's a discount.
Via covert influence there in terms of the economy et cetera, et cetera, but yeah. We were pleased to see that we see people on an anecdotal level being highly engaged to they're the ones and doing the code word, but the others as well we do we were done we're just working the code space.
Across a number of obviously programs are only a portfolio that employees of two to Amanda to a woman of stepped up extremely well so I'm very proud of of what they've done and.
Expected there will be will come out of this nicely and go well into into next year's on I think we're ready for the for the growth through two to restart and to continue well into the next year and beyond.
Thank you and my second question I guess within the strength that you're seeing in FSP.
How much of it is due to sticky nature of the business given that employees are embedded in the biopharma customers organization and the Skype for business and how much of background I could before from our share gains.
I think it's probably a bit of both one as I alluded to we we won some significant.
Programs and partnerships like last year, which is we delivered on extremely well I believe our customers are very happy with the with what we've been doing there. So I think that's a that's an important component.
I think there's some stickiness.
In that area as as I say isn't it more NFC business people build relationships with the customers with the sites and I think our customers are less.
You know less willing to sort of let that go even if there is a little bit of as you know a downtime we saw us being less accessible et cetera et cetera. So I think would benefit we've benefited on on both fronts from NFS people to be.
Thank you.
Thank you. The next question comes from the line of Patrick Donnelly from Citigroup, Patrick was guidelines how often.
Thanks, guys, maybe just one on the the remote monitoring virtual trial side clearly sounds like this is going to be a larger part of the market going forward.
No. It's early but are you seeing any increased interest in any particular areas for this type of work and then also just wanted to confirm the profitability. There I believe the beast about higher but just wanted to confirm that in any commentary there would be helpful.
Yeah, I'll take the I'll take the therapeutics, all things that maybe Brendan can talk about the profitability.
In terms of remote monitoring as as I said, we would slip into our 5% before the pandemic went to 60% now it's kind of I would say normalize a little bit back to back to around 30% to their visit spin on side of things being sort of being remote 30% thing remote and so you know it's moved around.
Quite a bit and in terms of the areas. We've typically seen this sort of work being in the more light phase areas, but will but but I think the pandemics really challenged us to work right across the therapeutic spectrum and right across the geographies gives us a.
A significant amount of flexibility in terms of the whereabouts of the people who are doing that I could have people sitting in Europe.
Doing remote monitoring for sites in the U.S. and vice versa, even in other parts of the world. So it does give us some real geographic flexibility, we pushed out fills that I think the industry's pushing ourselves in terms of the access to a to starts obviously you do need to have access to the electronic medical records and they're a very.
Yes, as you will note privacy and HIPPA related regulations GDPR that we have to fulfill their and that's a very important part of it and we've got to get there's more work to do in that area I think I'd I'd hesitate to say thats, all completely sorted out and there's a little bit of we've seen in Europe, a little thats a little bit higher.
To to organize into Ryan's than it has been in the United States. So there are some various geographical constraints, but I think there's aside the pandemic is really challenged as old to think a bit more different I think I saw the boxes I side and that's been I think a positive thing.
Brendan Mutt comment on the on the sort of potential margins on in this area, but we certainly see more flexibility more ability to adjust out.
Our resources there.
Yeah. Thanks, Dave.
Project, it's an interesting models because obviously you know there's the you know the element of course that goes back to the sponsor did that relation to for example, travel LCR raises is not there. So there's a more cost efficient non are all doing those are those business if you like than than the traditional methodology that no one.
Trial to Steve's point will be completely a remote or so we always be some elements of proportionality of our possibly both elements of physical on remote so that the margins I suppose you know when we look at them Eric dissimilar from the carrier bags as just the remote elements of those trials versus the actual when you're going to site, albeit.
As opposed proportionally there is less cost going back to the to the customer overall margin profiles are not dissimilar as I said each trial will have a mix of van or are those on them. So we very much manage the margins on on a byproduct basis. So we are thing is as they're being at a cost efficiency.
Really impacting on our margin profile.
Okay I appreciate that maybe just a quick one on the on the guidance side certainly encouraging to see you guys put that back on and sounds like the ways are down and cancellations are down piece recruitment seems like it's stabilizing and good to hear the upward trend is going to continue I'm just curious on your visibility kind of sitting here today.
Comfortable you are with kind of putting that guidance range back out there I'm. Obviously again continues to be a lot of variable to treat the cobot recruitments and.
Potential second ways. It's just wondering again on your level of visibility compared to past quarters, how comfortable you are with that range.
Yeah, well is you know it's it's it's certainly we don't have as much visibility or certainly as we had in past quarters. I think that's that's clear. However, we've certainly got a lot more visibility than we had a you know two or three months ago. So we do believe it's the is the right thing to do we can see definite progress.
Happening.
Within our operational groups around the as I sought accessibility site initiation, starting to really ramp up and get back almost to sort of normal levels and recruitment enrollment starting certainly moving the right direction on a week by week dice and so on that basis and we've been we've we obviously look at these metrics are pretty assiduously.
On a week to week, David David type basis, and we've seen here, it's not a it's got a just a one or two week patent we've seen a consistent pattern of increased availability of sites over the last 10, or so I took eight weeks or so from a pretty low advice and so on that prices. We do believe that were.
Able to to offer guidance.
In the spirit and ended two relatively broad range I suppose, but we do we do recognize this potential.
For for some volatility in the market and in the in the in the clinical environment given.
Tend to shutdowns, it, but even allowing for that we believe were able to two to offer in that in that range and for it to be a.
A realistic.
And forthright.
Set of figures there better do you want to Adena.
No just as a project of course, we have given us a broad range as he says of space of two quarters, which brought on we would normally think adventure and I felt that gives you. Some idea that there is still risk.
And the rest of the range or address the year in the profile of how has that my comes Pos.
Yes makes sense I appreciate it guys.
Thank you. My next question comes from the lines Tyco Peterson from JP Morgan. Please go ahead, Sir your line is now okay.
Thanks, I'll start with.
Backlog from my past some set yet my Teradata labs Templeton, putting in the faster burn uncoated work do you see backlog burn getting north of 8%.
Hearing in the third and fourth quarter and then on the operating margin question. Neil Bob's question earlier I didn't hear you quantify it that previously you talked about operating margin compression of 2% over the coming quarters. So in the context of that can you just give us a sense of the magnitude that you're talking about on operating margins in the back half area.
I'd like to pick up on that Psycho. So I think as it was hard good hard here at the beginning but I think your question related to our burn rate over the back half of the year at given that we have to covert mix of trial were coming in I. Suppose if you look at the midpoint of our guidance range and you do is going to do the math quickly it kind of indicate that will be coming back up towards that 8%.
Range for the back ended the year, but probably not in excess of it. So our R&D at the moment is that we got to seven Okay got it right at the end at the end of the year and then on just on the margin profile that we go through the back to core is a you're quite right. We could make that reference about 2% of arrange listen as we get to the fourth quarter.
We say, we want to try to I can come back to something that looks like a normal quarter for icon and obviously that would be more like what you've seen historically farmers in terms of you know that kind of.
Margin range, starting in the Fifteens and saw the stats you know that's another couple upside from where we are today. So that's that's exactly what we're trying to get too as we exit the year certainly made up of the average for the whole year, but certainly we're trying to get too.
Oh keen I'm wondering if he can talk on share dynamics, you know one of your competitor yesterday was adamant that they're taking share in this environment and as we've got a recovery can you just talked to the extent you think you're picking up share here.
Great around pricing as well.
Yeah, I think we are.
Since the competence and expertise in the vaccine space, Doug I think thats, certainly playing well with with our customers and so from that point of view, that's helping us.
Ontology remains an important part of our business as well we've been successful in that space notwithstanding some of the delays. So I think my perception is we are picking up share, particularly from the more middle mid size companies see arose but you know it's it's a desire it is early it all.
Early days and I'd say, we're in the middle of this pandemic of amendments or perhaps a little early to sort of declare victory on that one if we ever declare victory or market share.
But my perception is certainly the vaccine space, where we're a leading player and where we're playing those cards very well.
Thank you.
Thank you. The next question comes from the line of Sandy take brand from Suntrust. Please go ahead the lightest now.
Hi, Thank you very much a lot of that question to then asked maybe just.
Putting a pencil to that.
<unk> expense line, Brendan I think actually Steve had mentioned on the in the prepared remarks that basically expected expenses to stay flat.
As for there for the year I'm not sure if that was progress there, but then obviously in August you're going to push to the compensation backup which I'm sure is partially received by your your employees that maybe the offset adaptix expenses I'm just trying to reconcile those two statements are I may have missed center said something between those two comments.
No I think as Sallie, a you're quite right in states Collins prepared remarks, he said Doug that starting about the at the end of August when we do expect.
The absolute cost base dollar terms, probably to inflate as we go through the back to quarter. It certainly was keeping a close eye to cost of course, it's in the context of others have a decent lump all that revenue line and margins returning to something like as I said in my previous answer as somebody normal as we exit the year. So certainly got enough range it back up towards the 15th so.
No.
You know I think it is what has to follow the letter that we've been watching closely on cost base I think the dollars will increase but that will be a very very much offset by the bump in revenue that we're expecting a last couple quarters.
Okay, that's really helpful and my hopefully quick and and very unrelated follow up I bring that I didn't hear you gave an app acquisition contribution I know, it's not particularly meaningful I don't think so was there any.
Any material contribution from the acquisitions this quarter.
And the Sunday the business. So the numbers, where we were 10.8% down year on year Nazi Tams 10.3 in constant currency and 11.4 on a constant dollar organic basis.
Okay, great. Thanks, so much.
Well go next question comes from time to Donald Hooker from Keybanc Slide now going South.
Great Great Hello, everyone. So you reference you all reference in your prepared remarks.
Success with a slight network business and I'd be curious if that has been maybe you can elaborate on that reference has the site might work actually proved to be helpful.
In this environment I assume it's been open the whole time, so has that been helpful getting projects move toward versus having to rely on independent sites.
So don't Steve Yeah, I would say the subtenant, where it has been has been helpful. But I don't want a lot of is that it's certainly been impacted in several of them have had to be close they've been in geographies in regions, where we have had to close them down. So it hasn't quite had the impact that I was hoping overall, but generally.
Really it continues to contribute disproportionately and I'm with you know we're pleased with the progress with we're making in that space and in these sorts of.
And they sort of pandemics.
Having having more opportunity to draw as end to end to work with the sites because we have our people embedded has certainly bring a I believe in advantage, particularly for ongoing trials in pursuing patients who we want to keep moving along in those trials and making sure the trials and we had even if we weren't able always through it.
You should start as quickly as we'd like.
The ongoing trials have been kept in good shape and Thats, playing a very important component because of what we've done the overall overall positive.
Bob as I certainly been impacted no question about that.
Okay. Thank you and then maybe just real quick follow up from you guys reference obviously working on Coke in 19 projects. Several times did you ever can you maybe is it possible that set of roughly quantify sort of the mix of your bookings this quarter.
From Colgate, making.
I think I think our reference to previous question was drawn above.
We were well above 20% of of out of our wins this quarter. So yeah. It's a it's a good proportion although a wins in a again reflects our believes the expertise in competence, we have in that in that space. So.
Okay. Thank you sorry, I missed that thank you.
Your next question comes from lineup that morning.
[noise], we've got them Brennan for now I could yeah, Dan Bonnie is like Oh, great. Thanks, I hasten Brendan thanks.
You welcome.
Steve I think you made mention the beginning on your prepared remarks about a piece of openings and I know, you're giving from metrics wrap the call bye.
Get any assumptions came from me one Cooper from your first quarter call. I think you back then it felt 80% to 90% of decide to be up and running by year end I know you're at 60% or impacted today. So maybe just speak through the pace of opening that's kinda assumed I know you also mentioned enrollment is at 40% you know maybe maybe she can give us.
Kind of how we think about the progression of those metrics in year end.
Yeah, There I think I did you say, you're right I called out on the with the first quarter cool that we'd be sort of.
80% by yearend.
Don't have any reason to think thats going to be dramatically different I think I said, we'd been we'd be going into next year and I still believe we're going to be going well into next year by the time with all sorts of a back and that really assumes no significant shutdowns or lockdowns in the in the in the fall.
I would kind of on track with that as you said earlier, we are sort of 60% of sorts impacted in some way, 40% pretty much are effective back to normal.
So that the progress were making would get us I think around the 80% by the by the fourth quarter, but we're gonna be well into first quarter next year, even perhaps into second quarter before we feel with right back and that's pretty much in line with I think what have been what would be planning and what we've been expecting that would the moment I think.
Demand there you know with projects coming back online I think we'll see enrollment start to ramp up even a little faster, perhaps and then the site availability.
But I still think we're going to be into the first quarter will be well into the first quarter before we're back on.
You know at 100% a pre covered enrollment.
Great and then longer maybe really sorry, sorry that notwithstanding some bump, we'll probably get from the vaccine enrollment.
That will sort of cover it sort of a multitude of since does that make sense in the next couple of months because there will be some significant enrollment I think in the third and fourth quarter around vaccines, but the underlying sort of ongoing I think we'll take into the first quarter came from.
Great. Thanks.
And then kind of member maybe related to that so.
On the base business that will get back to normal by the middle of next year, but obviously cobot on top so I mean, we get put those two together.
Possible by 21 could be back to where you were previously when you're correct, obviously, I don't know where 20% of.
20, plus kinda back aren't going to probably could go further higher as we go for the next couple of quarters. So I'm, just not going to give a 21 of them it down but I'm. Just wondering you got comfortable that you know whatever you want to prior for your 21 revenue could that go beyond the cable if things play out Rebecca Conrad electric given how much capacity.
Oh, I've, a cracker than in Britain might jump in I think I think whatever we were thinking prize is perhaps a bit of a stretch.
Dan I see I'm thinking at the moment of 2020 being a little bit of a last year kind of thing is the while I'm thinking Oh, I hope to be proven wrong and I hope that we'll we'll move on and 2021 will be better than.
What 2020 would have brain if that makes sense I expect that probably will be the case that I'm not ready to declare victory on that one year 2020 has been a challenging you I think we've still got some challenges to to work through and although we certainly see some light at the end of the touched on some optimism in terms of reawakening in reopening of.
Besides.
There is plenty of risk out there that we have to be cognizant of and planning for a and ended the coated work I think gives us some opportunity to the relatively short term to move things along but the underlying business also needs to leads to move forward and that's I think that that can still be impacted obviously by.
This this pandemic and further Lockdowns Brendan did you want to jump in I know I don't think I doubt that they like that that's spot on with a focus is to you know gets you back ended this year and then the idea of a 21 as as we see the hope is that yeah. It'll be designed to next question comes from the line of George Hill from Deutsche Bank. Please go ahead your today.
Smells them.
George has done a day.
Yeah.
Good morning America.
Yeah.
Well David.
George if you're on me, but I mean, you so quickly.
I'll break it out I think George is going to ask that goes into maybe want to get to excellent.
Yep.
Okay.
[noise].
Operator.
Operator, you there.
Yes, I'm a moment I'm, having trouble connecting my line is burden.
Okay.
[noise].
<unk>.
<unk>.
Okay.
Uh huh.
Operator, we can answer the top of the hours is there. If there are there any other questions can connect those loans, yes, our outlook for someone to a sticky or next question.
One of our or her on that just suggested you're thinking.
Our stops on wall or waiting to see whether that's a [laughter] yeltsin's effect.
Right, that's the and I wouldn't want to hear amazing at Ares and some assessment you.
Embodies the rather than made Brandon.
[noise] [noise] [noise].
I think we could follow up with the with the analysts after it's perhaps yeah.
That's probably the best thing to do a operator doesn't sell others Christian to.
You're going to be able to be connected.
Right.
Okay, well, well and like I said I've gone the basically rocket technical difficulties policies to those who are on the line. It might go to do some of it.
So yeah apologies for for a normal onto that I'm not quite sure. What's the what's gone wrong will certainly follow up with the Jugend and Dave on those questions.
Just in concluding I'd like to thank everyone for listening in today, there is the impact as the co but not in pandemic continues to evolve out we provided some some good information on that our bodies focused on protecting the safety and well being of our employees and patients and of course continuing to service. The important would we undertake on behalf of our cost.
Ms and in turn preserving the strength of our of our business.
So I want to take this opportunity again at the recognize our entire workforce and thank them for their tireless efforts and ongoing zillions during what's been a incredibly challenging period that that will need to keep working through as well. Thank you everyone in the rest of that.
[noise].
[music].
[noise].
[music].